Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Libo Sun

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Genes & Diseases|February 28, 2022
Protein phosphatase 6 (Pp6) is crucial for regulatory T cell function and stability in autoimmunityWei Cai, Junxun Zhang, Hong Zhou, et al.
The Journal of Investigative Dermatology|January 15, 2022
Lidocaine Ameliorates Psoriasis by Obstructing Pathogenic CGRP Signaling‒Mediated Sensory Neuron‒Dendritic Cell CommunicationQianqian Yin, Libo Sun, Xiaojie Cai, et al.
Science Advances|July 17, 2020
A micropeptide encoded by lncRNA MIR155HG suppresses autoimmune inflammation via modulating antigen presentationLiman Niu, Fangzhou Lou, Yang Sun, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 23, 2021
SZB120 Exhibits Immunomodulatory Effects by Targeting eIF2α to Suppress Th17 Cell DifferentiationLinjiao Chen, Jing Bai, Danhong Peng, et al.
Future Oncology (London, England)|May 5, 2022
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study designJohn Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, et al.
EMBO Reports|March 28, 2022
A peptide encoded by pri-miRNA-31 represses autoimmunity by promoting T<sub>reg</sub> differentiationHong Zhou, Fangzhou Lou, Jing Bai, et al.
Haematologica|January 22, 2026
Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge studyMikkael A Sekeres, Amer M Zeidan, Valeria Santini, et al.
Blood Neoplasia|April 24, 2026
Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trialMikkael A Sekeres, Valeria Santini, Amer M Zeidan, et al.
Immunity|June 20, 2020
Excessive Polyamine Generation in Keratinocytes Promotes Self-RNA Sensing by Dendritic Cells in PsoriasisFangzhou Lou, Yang Sun, Zhenyao Xu, et al.
Leukemia & Lymphoma|November 13, 2024
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge studyMikkael A Sekeres, Valeria Santini, Maria Díez-Campelo, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Genes & Diseases|February 28, 2022
Protein phosphatase 6 (Pp6) is crucial for regulatory T cell function and stability in autoimmunityWei Cai, Junxun Zhang, Hong Zhou, et al.
The Journal of Investigative Dermatology|January 15, 2022
Lidocaine Ameliorates Psoriasis by Obstructing Pathogenic CGRP Signaling‒Mediated Sensory Neuron‒Dendritic Cell CommunicationQianqian Yin, Libo Sun, Xiaojie Cai, et al.
Science Advances|July 17, 2020
A micropeptide encoded by lncRNA MIR155HG suppresses autoimmune inflammation via modulating antigen presentationLiman Niu, Fangzhou Lou, Yang Sun, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 23, 2021
SZB120 Exhibits Immunomodulatory Effects by Targeting eIF2α to Suppress Th17 Cell DifferentiationLinjiao Chen, Jing Bai, Danhong Peng, et al.
Future Oncology (London, England)|May 5, 2022
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study designJohn Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, et al.
EMBO Reports|March 28, 2022
A peptide encoded by pri-miRNA-31 represses autoimmunity by promoting T<sub>reg</sub> differentiationHong Zhou, Fangzhou Lou, Jing Bai, et al.
Haematologica|January 22, 2026
Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge studyMikkael A Sekeres, Amer M Zeidan, Valeria Santini, et al.
Blood Neoplasia|April 24, 2026
Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trialMikkael A Sekeres, Valeria Santini, Amer M Zeidan, et al.
Immunity|June 20, 2020
Excessive Polyamine Generation in Keratinocytes Promotes Self-RNA Sensing by Dendritic Cells in PsoriasisFangzhou Lou, Yang Sun, Zhenyao Xu, et al.
Leukemia & Lymphoma|November 13, 2024
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge studyMikkael A Sekeres, Valeria Santini, Maria Díez-Campelo, et al.
Pageof 15